what phase is retatrutide in Commercial Availability Timeline: Key Milestones and Costs Phase III retatrutide study demonstrates

These indicate autophagy is a key molecular event for GLP-1R agonists to protect neurons against damage

Semaglutide activates GLP-1 receptors throughout the body in the pancreas, gut, and critically in the brain, particularly in the hypothalamic arcuate nucleus and reward-processing regions of the mesolimbic system

But these medications can present challenges, including gastrointestinal side effects, risk of micronutrient deficiencies, muscle and bone loss, poor long- term adherence with subsequent weight regain, and high costs

Four states eliminated coverage in that window: California, New Hampshire, Pennsylvania, and South Carolina